Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 7 of 7 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/17
End: 09/30/17
Due: 09/30/18
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Phase: N/A
Priority: Normal
Start: 11/30/15
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/31/16
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/16
End: 02/28/17
Due: 02/28/18
Phase: N/A
Priority: Normal
Start: 03/31/12
End: 03/31/13
Due: 03/31/14
Phase: N/A
Priority: Normal
Start: 10/17/16
End: 11/06/18
Due: 11/06/19
Phase: N/A
Priority: Normal
Start: 12/31/15
End: 02/28/17
Due: 02/28/18